<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514669</url>
  </required_header>
  <id_info>
    <org_study_id>133719</org_study_id>
    <nct_id>NCT01514669</nct_id>
  </id_info>
  <brief_title>Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer</brief_title>
  <official_title>Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare profiles in the blood and tears of patients&#xD;
      with and without prostate cancer with the goal of developing a method of separating men with&#xD;
      aggressive and non-aggressive disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tear Sample</measure>
    <time_frame>1 day</time_frame>
    <description>Tear sample will be taken at the initial clinic visit</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <description>No Tx, this is observational</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tear Sample collection; serum sample collection&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be selected from those outpatients followed in the Winthrop P.&#xD;
        Rockefeller Cancer Institute (located at the University of Arkansas for Medical Sciences).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male, 35-85 years old&#xD;
&#xD;
          2. Patients who present for the evaluation of an abnormal exam or test (elevated PSA,&#xD;
             abnormal DRE, etc.)&#xD;
&#xD;
          3. Patients who present for the evaluation of a palpable nodule or induration on prostate&#xD;
             exam&#xD;
&#xD;
          4. Patients who meet the requirements of Group 1, 2, or 3 of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient &lt; 35 or &gt; 85 years of age&#xD;
&#xD;
          2. Concurrent eye infection or trauma, including active conjunctivitis&#xD;
&#xD;
          3. Abnormal production of tears (too much or too little)&#xD;
&#xD;
          4. Any other conditions the PI or staff feels will not fulfill the criteria for study&#xD;
             entry or will place the subject in a harmful environment&#xD;
&#xD;
          5. Atypia on prostate biopsy report&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Diekman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2012</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

